Clonal alterations in hematopoietic cells occur during aging and are often associated with
the establishment of a subclinical inflammatory environment. Several age-related conditions …

JAK inhibitors have been developed following the discovery of the JAK2V617F in 2005 as
the driver mutation of the majority of non-BCR-ABL1 myeloproliferative neoplasms (MPNs) …

Since its approval in 2011, the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib has evolved to
become the centerpiece of therapy for myelofibrosis (MF), and its use in patients with …

Following the discovery of the JAK2V617F mutation in myeloproliferative neoplasms in
2005, fedratinib was developed as a small molecular inhibitor of JAK2. It was optimized to …

The Janus kinase (JAK) signal transducer and activator of transcription (JAK-STAT) pathway
is an evolutionarily conserved mechanism of transmembrane signal transduction that …

Signal Transducer and Activator of Transcription (STAT) 3 and 5 are important effectors of
cellular transformation, and aberrant STAT3 and STAT5 signaling have been demonstrated …

Abstract Purpose of Review Chronic myeloproliferative neoplasms (MPN) represent a group
of diseases characterised by constitutive activation of the JAK/STAT pathway in a clonal …

Predicting the response of each individual patient to a drug is a key issue assailing
personalized medicine. Our study predicted drug response based on the fusion of …

The development of targeted therapies for the treatment of myelofibrosis highlights a unique
issue in a field that has historically relied on symptom relief, rather than survival benefit or …

Background: JAK/STAT signal pathway, a requisite part in the signaling process of growth
factors and cytokines, has become attractive targets for numerous immune, inflammatory …